Cardiometabolic Health Congress

NOVEMBER 14, 2024

42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. In the U.S., SELECT Trial Results : Semaglutide 2.4

CME 103

CME Obesity Heart Failure Biomarkers 103

Cardiometabolic Health Congress

OCTOBER 25, 2024

Attendees dove into cutting-edge topics, including FDA updates, resistant hypertension, and cardiac biomarkers. “I Florez, MD, PhD , explored the future of precision medicine in diabetes. The 20th Annual CMHC, an anniversary celebration, is already on the horizon, set for October 23-25, 2025, in Boston. Learn more now!

CME 64

CME Innovation Education Atherosclerosis 64

Dr. Malcolm Kendrick

OCTOBER 30, 2024

(2022-25) Swiss Reinsurance Company: £645K China Kadoorie Biobank (2002-ongoing) AstraZeneca: $300K Bayer AG: £300K GlaxoSmithKline: £3.6M Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M Establishing Fuwai-Oxford research centre (2010-ongoing) Merck: £1.1M

Cholesterol 145

Cholesterol Article Research Diet 145